Head-to-head · free
PDS Biotechnology Corporation vs uniQure
PDSB vs QURE — return on capital, cash generation, margins and balance sheet side by side.
PDSB
2 / 3
measures where PDSB leads
QURE
1 / 3
measures where QURE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PDSB · FY2025 | QURE · FY2025 |
|---|---|---|
| Revenue | — | — |
| Net income | (8.5M) | (199.0M) |
| Revenue growth (yearly, multi-year) | — | -47.8% |
| Free cash flow | (27.8M) | (178.4M) |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -244.2% | — |
| Gross margin | — | 89.5% |
| Operating margin | — | -1166.8% |
| Net debt / EBITDA | 0.31x | 0.18x |
Figures are as reported by each company; latest fiscal year shown.
Where PDS Biotechnology Corporation's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where uniQure's cash went (FY2025)
- Capital spending
- $439000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free